| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago | ||
| Di | FDA approves leucovorin for ultrarare cerebral folate deficiency subset without clinical trial | ||
| Mo | FDA unveils 4th revision of draft guidance for looser biosimilar testing requirements | ||
| Mo | Lilly rewards CEO David Ricks with $36.7M pay package for 2025, fueled by GLP-1 success | ||
| Mo | Spruce hooks a commercial chief to prep for rare disease launch | ||
| Mo | Novo and Hims make nice, striking deal to sell Ozempic, Wegovy on Hims' telehealth platform | ||
| Mo | Sotyktu take 2: BMS' first-in-class pill gains FDA nod to treat psoriatic arthritis | ||
| Mo | 'SNL' pokes fun at mysteries of Amgen's Otezla for plaque psoriasis | ||
| Mo | Novo's troubled Indiana plant claims another victim as FDA rejects Incyte's lung cancer application | ||
| Mo | Ipsen backs away from cancer med Tazverik after safety signals emerge in lymphoma trial | ||
| 06.03. | Lonza hands off capsule business to investment firm Lone Star in $3B deal | ||
| 06.03. | Democrats press 11 pharmas for 'any evidence' their Trump pricing deals deliver savings for Medicaid | ||
| 06.03. | Sanofi strikes deal with Brazil's EMS to sell generics manufacturer Medley | ||
| 06.03. | Super Bowl, Winter Olympics defined TV drug ad spending in February, led by AbbVie's Rinvoq | ||
| 06.03. | Pfizer breaks into obesity market in China with approval for Sciwind-partnered GLP-1 | ||
| 06.03. | Taiwan earmarks $755M for multi-year drug supply resilience program | ||
| 06.03. | Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda | ||
| 06.03. | Fierce Pharma Asia-Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC | ||
| 05.03. | Forma Life Sciences launches with oral solid dose focus, joining class of new CDMOs | ||
| 05.03. | FDA gives Glenmark thumbs up for first 'true' generic version of GSK's asthma inhaler Flovent | ||
| 05.03. | After generic defense fails, Merck KGaA assumes no US Mavenclad sales after March | ||
| 05.03. | Galderma doubles Nemluvio peak sales projection to $4B-plus after strong atopic dermatitis launch year | ||
| 05.03. | Leo roars onto Netflix with DTC campaign for new hand eczema cream Anzupgo | ||
| 04.03. | Collegium enrolls Paris Hilton in Jornay PM push encouraging ADHD community to 'Embrace Your Sparkle' | ||
| 04.03. | FDA answers Vanda's yearslong call for public hearing on unsuccessful jet lag approval bid |